BOSTON -- Shares of Orexigen Therapeutics jumped 10% Monday morning. The U.S. Food and Drug Administration is expected to issue a decision by the end of Monday on whether it will approve Orexigen's diet drug Contrave.

Copyright © 2011 MarketWatch, Inc.